{"DataElement":{"publicId":"6734070","version":"1","preferredName":"Single and Combination Agent Treatment Regimen Name","preferredDefinition":"The response that indicates the name of the regimen administered to the patient.","longName":"AGT_TRT_REG_NAME","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"5260832","version":"1","preferredName":"Treatment Regimen","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._ A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"2416951v1.0:2177402v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177402","version":"1","preferredName":"Regimen","preferredDefinition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"Regimen","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-527D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"32B88FFE-0CE6-8F58-E050-BB89AD431821","latestVersionIndicator":"Yes","beginDate":"2016-05-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-05-13","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created as requested by K.Wildermuth. mc 5/13/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6733221","version":"1","preferredName":"Single and Combination Agent Regimen Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"6733221v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other (specify)","valueDescription":"Other","ValueMeaning":{"publicId":"2757951","version":"1","preferredName":"Other","longName":"2757951","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F52A8FB-E278-3426-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Added concept to value meaning. mc 3/20/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-40EB-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Bleomycin/Cyclophosphamide/Doxorubicin/Prednisone/Procarbazine/Vincristine","valueDescription":"CAP-BOP","ValueMeaning":{"publicId":"3366681","version":"1","preferredName":"CAP-BOP","longName":"3366681","preferredDefinition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisone, procarbazine, and vincristine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BACOPP Regimen","conceptCode":"C9564","definition":"A chemotherapy regimen consisting of bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone that can be used for the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1006E-725D-FDDD-E040-BB89AD437842","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-40FF-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"CHOP Regimen","valueDescription":"CHOP Regimen","ValueMeaning":{"publicId":"3378205","version":"1","preferredName":"CHOP Regimen","longName":"3378205","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-737A-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4114-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"R-CHOP Regimen","valueDescription":"R-CHOP Regimen","ValueMeaning":{"publicId":"6002915","version":"1","preferredName":"R-CHOP Regimen","longName":"6002915","preferredDefinition":"An immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-CHOP Regimen","conceptCode":"C9760","definition":"A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenstr√∂m macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EB68A-E226-6286-E053-F662850A0582","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4128-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"CHOPE Regimen","valueDescription":"CHOPE Regimen","ValueMeaning":{"publicId":"6010535","version":"1","preferredName":"CHOPE Regimen","longName":"6010535","preferredDefinition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide used to treat both indolent and aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOPE Regimen","conceptCode":"C9702","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide that may be used to treat primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, and other forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64899D-8F3B-5E4E-E053-F662850AF522","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-413D-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"CNOP Regimen","valueDescription":"Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine","ValueMeaning":{"publicId":"3366722","version":"1","preferredName":"Cyclophosphamide/Mitoxantrone/Prednisone/Vincristine","longName":"3366722","preferredDefinition":"A regimen consisting of cyclophosphamide, mitoxantrone, vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CNOP Regimen","conceptCode":"C63453","definition":"A regimen consisting of cyclophosphamide, mitoxantrone, vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5367-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4152-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"COPP Regimen","valueDescription":"COPP Regimen","ValueMeaning":{"publicId":"3368104","version":"1","preferredName":"COPP Regimen","longName":"3368104","preferredDefinition":"A derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin's lymphoma. Also used for the treatment of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"COPP Regimen","conceptCode":"C9567","definition":"A derivative of the original MOPP regimen consisting of cyclophosphamide, vincristine, procarbazine and prednisone used as an initial treatment for Hodgkin lymphoma. Also used for the treatment of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7D59407-7E14-B72A-E040-BB89AD432902","latestVersionIndicator":"Yes","beginDate":"2012-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4167-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"CVP Regimen","valueDescription":"CVP Regimen","ValueMeaning":{"publicId":"3366718","version":"1","preferredName":"CVP Regimen","longName":"3366718","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine and prednisone used to treat indolent forms of non-Hodgkin's lymphoma; also used for the treatment of chronic lymphocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CVP Regimen","conceptCode":"C9573","definition":"A regimen consisting of cyclophosphamide, vincristine and prednisone that may be used to treat Castleman disease, post-transplant lymphoproliferative disorders, indolent forms of non-Hodgkin lymphoma and chronic lymphocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-531B-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-417B-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"F-MACHOP Regimen","valueDescription":"5-Fluorouracil, Methotrexate with Leucovorin Rescue, Cytarabine, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","ValueMeaning":{"publicId":"3366716","version":"1","preferredName":"5-Fluorouracil, Methotrexate with Leucovorin Rescue, Cytarabine, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","longName":"3366716","preferredDefinition":"A chemotherapy regimen consisting of 5-fluorouracil, methotrexate with leucovorin rescue, cytarabine, cyclophosphamide, doxorubicin, vincristine, and prednisone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"F-MACHOP Regimen","conceptCode":"C99697","definition":"A chemotherapy regimen consisting of 5-fluorouracil, methotrexate with leucovorin rescue, cytarabine, cyclophosphamide, doxorubicin, vincristine, and prednisone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-52F5-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-418F-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"EPOCH Regimen","valueDescription":"EPOCH Regimen","ValueMeaning":{"publicId":"3378980","version":"1","preferredName":"EPOCH Regimen","longName":"3378980","preferredDefinition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin) and doxorubicin hydrochloride (hydroxydaunorubicin hycrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EPOCH Regimen","conceptCode":"C63779","definition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9086113-33C6-38C1-E040-BB89AD43581C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-41A4-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"R-DA-EPOCH  Regimen","valueDescription":"R-DA-EPOCH  Regimen","ValueMeaning":{"publicId":"6002924","version":"1","preferredName":"R-DA-EPOCH  Regimen","longName":"6002924","preferredDefinition":"A regimen consisting of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in a dose-adjusted (DA) version that can be used for the treatment of non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose-adjusted EPOCH-R Regimen","conceptCode":"C140097","definition":"A regimen consisting of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in a dose-adjusted (DA) version that can be used for the treatment of AIDS-related B-cell lymphomas, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7ECD-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-41B8-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"High-dose Methotrexate/Leucovorin Regimen","valueDescription":"High-dose Methotrexate/Leucovorin Regimen","ValueMeaning":{"publicId":"6733223","version":"1","preferredName":"High-dose Methotrexate/Leucovorin Regimen","longName":"6733223","preferredDefinition":"A regimen consisting of high-dose methotrexate and leucovorin that can potentially be used for the treatment of various central nervous system (CNS) cancers and various types of lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leucovorin/High-dose Methotrexate Regimen","conceptCode":"C156264","definition":"A regimen consisting of high-dose methotrexate and leucovorin that can potentially be used for the treatment of various central nervous system (CNS) cancers and various types of lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"877335D6-41C6-7B53-E053-F662850A3265","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-41DF-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"ICE Regimen","valueDescription":"ICE Regimen","ValueMeaning":{"publicId":"3366711","version":"1","preferredName":"ICE Regimen","longName":"3366711","preferredDefinition":"A chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of relapsed and refractory non-Hodgkin and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ICE Regimen","conceptCode":"C10345","definition":"A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia. Paclitaxel/carboplatin/oral etoposide regimen can be used for the treatment of occult primary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5264-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-41F3-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"R-ICE Regimen","valueDescription":"R-ICE Regimen","ValueMeaning":{"publicId":"6010539","version":"1","preferredName":"R-ICE Regimen","longName":"6010539","preferredDefinition":"A chemoimmunotherapy regimen consisting of rituximab, ifosfamide, carboplatin and etoposide used to treat indolent and aggressive forms of non-Hodgkin's lymphoma; also used to treat relapsed and refractory non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-ICE Regimen","conceptCode":"C63465","definition":"A regimen consisting of rituximab, ifosfamide, carboplatin and etoposide that can be used for the treatment of nodular lymphocyte-predominant Hodgkin lymphoma and certain forms of non-Hodgkin lymphoma (NHL), such as Burkitt lymphoma and diffuse large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64ADD9-38C5-3F16-E053-F662850A65BD","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4207-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Bleomycin/Cyclophosphamide/Doxorubicin/Prednisolone/Vindesine","valueDescription":"LNH-84","ValueMeaning":{"publicId":"3366708","version":"1","preferredName":"LNH-84","longName":"3366708","preferredDefinition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisolone, and vindesine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bleomycin/Cyclophosphamide/Doxorubicin/Prednisolone/Vindesine Regimen","conceptCode":"C10783","definition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, prednisolone, and vindesine that can be used for the treatment of lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-521B-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-421C-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"ACVBP Regimen","valueDescription":"LNH-87","ValueMeaning":{"publicId":"3366707","version":"1","preferredName":"LNH-87","longName":"3366707","preferredDefinition":"A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACVBP Regimen","conceptCode":"C63446","definition":"A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-51F8-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4231-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"M-BACOP Regimen","valueDescription":"M-BACOP","ValueMeaning":{"publicId":"3366706","version":"1","preferredName":"M-BACOP","longName":"3366706","preferredDefinition":"A chemotherapy regimen consisting of methotre xate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisolone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"M-BACOP Regimen","conceptCode":"C99696","definition":"A chemotherapy regimen consisting of methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisolone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-51D5-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4246-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"MACOP-B Regimen","valueDescription":"MACOP-B Regimen","ValueMeaning":{"publicId":"3366705","version":"1","preferredName":"MACOP-B Regimen","longName":"3366705","preferredDefinition":"A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MACOP-B Regimen","conceptCode":"C63457","definition":"A regimen consisting of methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and prednisone, used to treat aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-51B2-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-425B-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"ProMACE-CytaBOM Regimen","valueDescription":"ProMace-CytaBOM Regimen","ValueMeaning":{"publicId":"3366704","version":"1","preferredName":"ProMace-CytaBOM Regimen","longName":"3366704","preferredDefinition":"A non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with cytarabine, bleomycin, vincristine and methotrexate (CytaBOM), used to treat aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ProMACE Alternating with CytaBOM Regimen","conceptCode":"C63460","definition":"A non-cross resistant regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide and etoposide (ProMACE) alternating with cytarabine, bleomycin, vincristine and methotrexate (CytaBOM), used to treat aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-518F-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-426F-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Cyclophosphamide/Doxorubicin/Etoposide/Mechlorethamine/Methotrexate/Prednisone/Procarbazine/Vincristine","valueDescription":"ProMace-MOPP","ValueMeaning":{"publicId":"3366703","version":"1","preferredName":"ProMace-MOPP","longName":"3366703","preferredDefinition":"A chemotherapy combination consisting of cyclophosphamide, doxorubicin, etoposide, mechlorethamine, methotrexate, prednisone, procarbazine, and vincristine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ProMACE-MOPP Regimen","conceptCode":"C9679","definition":"A chemotherapy regimen consisting of prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide (ProMACE) followed by mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) that may be used in the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-516C-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4284-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Bleomycin/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine","valueDescription":"VACOP-B","ValueMeaning":{"publicId":"3366702","version":"1","preferredName":"VACOP-B","longName":"3366702","preferredDefinition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, etoposide, prednisone and vincristine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VACOP-B Regimen","conceptCode":"C11343","definition":"A chemotherapy combination consisting of bleomycin, cyclophosphamide, doxorubicin, etoposide, prednisone and vincristine that can be used for the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5149-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4299-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"HyperCVAD Regimen","valueDescription":"HyperCVAD Regimen","ValueMeaning":{"publicId":"6002978","version":"1","preferredName":"HyperCVAD Regimen","longName":"6002978","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, used to treat adult L3 acute lymphoblastic leukemia (ALL3 or Burkitt's-type) and adult small non-cleaved cell (Burkitt's) lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HyperCVAD Regimen","conceptCode":"C63455","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F089D-FFC0-475C-E053-F662850A6912","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-42AE-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"SMILE Regimen","valueDescription":"SMILE Regimen","ValueMeaning":{"publicId":"6002983","version":"1","preferredName":"SMILE Regimen","longName":"6002983","preferredDefinition":"A regimen consisting of dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide that can be used in the treatment of natural killer (NK)/T-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SMILE Regimen","conceptCode":"C140113","definition":"A regimen consisting of dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide that can be used in the treatment of natural killer (NK)/T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5C7B-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-42C3-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"AspaMetDex Regimen","valueDescription":"AspaMetDex Regimen","ValueMeaning":{"publicId":"6002271","version":"1","preferredName":"AspaMetDex Regimen","longName":"6002271","preferredDefinition":"A regimen consisting of L-asparaginase, methotrexate and dexamethasone that can be used for the treatment of non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AspaMetDex Regimen","conceptCode":"C140092","definition":"A regimen consisting of L-asparaginase, methotrexate and dexamethasone that can be used for the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5A5F30-7CFE-7D6E-E053-F662850AC99A","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-42D8-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Gemcitabine-Oxaliplatin Regimen","valueDescription":"Gemcitabine-Oxaliplatin Regimen","ValueMeaning":{"publicId":"6002932","version":"1","preferredName":"Gemcitabine-Oxaliplatin Regimen","longName":"6002932","preferredDefinition":"A regimen consisting of gemcitabine and oxaliplatin used for the treatment of biliary adenocarcinoma, pancreatic cancer, hepatocellular cancer and testicular cancer. This regimen is currently being studied in a variety of other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GemOx Regimen","conceptCode":"C64833","definition":"A regimen consisting of gemcitabine and oxaliplatin used for the treatment of biliary adenocarcinoma, pancreatic cancer, hepatocellular cancer and testicular cancer. This regimen is currently being studied in a variety of other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7F1B-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-42ED-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Brentuximab Vedotin","valueDescription":"Brentuximab Vedotin","ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-42F7-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Lenalidomide","valueDescription":"Lenalidomide","ValueMeaning":{"publicId":"3379210","version":"1","preferredName":"Lenalidomide","longName":"3379210","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B2FA-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4301-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Mogamulizumab","valueDescription":"Mogamulizumab","ValueMeaning":{"publicId":"5944042","version":"1","preferredName":"Mogamulizumab","longName":"5944042","preferredDefinition":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mogamulizumab","conceptCode":"C62510","definition":"A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E60930-FE7C-69F8-E053-F662850ABC19","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-430B-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"DHAP Regimen","valueDescription":"DHAP Regimen","ValueMeaning":{"publicId":"6002923","version":"1","preferredName":"DHAP Regimen","longName":"6002923","preferredDefinition":"A chemotherapy regimen consisting of dexamethasone, high-dose cytarabine (Ara-C) and cisplatin, used to treat relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DHAP Regimen","conceptCode":"C63441","definition":"A chemotherapy regimen consisting of dexamethasone, high-dose cytarabine (Ara-C) and cisplatin, used to treat relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7EA8-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-431F-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"ESHAP Regimen","valueDescription":"ESHAP Regimen","ValueMeaning":{"publicId":"6002938","version":"1","preferredName":"ESHAP Regimen","longName":"6002938","preferredDefinition":"A regimen consisting of etoposide, methylprednisolone, high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ESHAP Regimen","conceptCode":"C63377","definition":"A regimen consisting of etoposide, methylprednisolone, high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin and non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7FD3-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4334-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"GDP Regimen","valueDescription":"GDP Regimen","ValueMeaning":{"publicId":"6002934","version":"1","preferredName":"GDP Regimen","longName":"6002934","preferredDefinition":"A regimen consisting of gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GDP Regimen","conceptCode":"C140100","definition":"A regimen consisting of gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7F65-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4349-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"GVD Regimen","valueDescription":"GVD Regimen","ValueMeaning":{"publicId":"6010542","version":"1","preferredName":"GVD Regimen","longName":"6010542","preferredDefinition":"A regimen consisting of gemcitabine, vinorelbine and pegylated liposomal doxorubicin that can be used in the treatment of Hodgkin lymphoma (HL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GVD Regimen","conceptCode":"C140732","definition":"A regimen consisting of gemcitabine, vinorelbine and pegylated liposomal doxorubicin used for the treatment of Hodgkin lymphoma (HL), T-cell lymphomas, and mycosis fungoides and Sezary syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64ADD9-393E-3F16-E053-F662850A65BD","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-435E-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Bortezomib","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"5127395","version":"1","preferredName":"Bortezomib","longName":"5127395","preferredDefinition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FA1B-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4369-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Belinostat","valueDescription":"Belinostat","ValueMeaning":{"publicId":"3378157","version":"1","preferredName":"Belinostat","longName":"3378157","preferredDefinition":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Belinostat","conceptCode":"C48812","definition":"A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90390BA-6CDB-6B71-E040-BB89AD432BAA","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4373-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Romidepsin","valueDescription":"Romidepsin","ValueMeaning":{"publicId":"5342172","version":"1","preferredName":"Romidepsin","longName":"5342172","preferredDefinition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Romidepsin","conceptCode":"C1544","definition":"A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3765270F-39D0-8633-E050-BB89AD4330A5","latestVersionIndicator":"Yes","beginDate":"2016-07-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-07-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-437D-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Pralatrexate","valueDescription":"10-Propargyl-10-Deazaaminopterin","ValueMeaning":{"publicId":"3379489","version":"1","preferredName":"10-Propargyl-10-Deazaaminopterin","longName":"3379489","preferredDefinition":"A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pralatrexate","conceptCode":"C2250","definition":"A folate analogue inhibitor of dihydrofolate reductase (DHFR) exhibiting high affinity for reduced folate carrier-1 (RFC-1) with antineoplastic and immunosuppressive activities. Pralatrexate selectively enters cells expressing RFC-1; intracellularly, this agent is highly polyglutamylated and competes for the folate binding site of DHFR, blocking tetrahydrofolate synthesis, which may result in depletion of nucleotide precursors; inhibition of DNA, RNA and protein synthesis; and apoptotic tumor cell death. Efficient intracellular polyglutamylation of pralatrexate results in higher intracellular concentrations compared to non-polyglutamylated pralatrexate, which is more readily effuxed by the MRP (multidrug resistance protein) drug efflux pump. RFC-1, an oncofetal protein expressed at highest levels during embryonic development, may be over-expressed on the cell surfaces of various cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2623-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4387-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Bendamustine","valueDescription":"Bendamustine","ValueMeaning":{"publicId":"4862971","version":"1","preferredName":"Bendamustine","longName":"4862971","preferredDefinition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bendamustine","conceptCode":"C73261","definition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1842453B-10A4-C393-E050-BB89AD436354","latestVersionIndicator":"Yes","beginDate":"2015-06-11","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-06-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-4391-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"5242658","version":"1","preferredName":"Gemcitabine","longName":"5242658","preferredDefinition":"The active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-98BB-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-439B-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"Alemtuzumab","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877335D6-43A5-7B53-E053-F662850A3265","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"GELOX","valueDescription":"GELOX Regimen","ValueMeaning":{"publicId":"6734268","version":"1","preferredName":"GELOX Regimen","longName":"6734268","preferredDefinition":"A regimen consisting of gemcitabine, oxaliplatin and asparaginase that can be used to treat extranodal natural killer (NK)/T‚Äêcell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GELOX Regimen","conceptCode":"C159560","definition":"A regimen consisting of gemcitabine, oxaliplatin and asparaginase that can be used to treat extranodal natural killer (NK)/T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87767AD4-6DFC-73A9-E053-F662850A7104","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87767AD4-6E15-73A9-E053-F662850A7104","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"CHP + Brentuximab vedotin","valueDescription":"CHP-Brentuximab Vedotin Regimen","ValueMeaning":{"publicId":"6734269","version":"1","preferredName":"CHP-Brentuximab Vedotin Regimen","longName":"6734269","preferredDefinition":"A regimen consisting of brentuximab vedotin, cyclophosphamide, doxorubicin and prednisone that can be used to treat CD30-expressing peripheral T-cell lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHP-Brentuximab Vedotin Regimen","conceptCode":"C159558","definition":"A regimen consisting of brentuximab vedotin, cyclophosphamide, doxorubicin and prednisone that can be used to treat T-cell lymphomas, primary cutaneous CD30+ T-cell lymphoproliferative disorders and post-transplant lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87767AD4-6E21-73A9-E053-F662850A7104","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87767AD4-6E3A-73A9-E053-F662850A7104","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"DHAX","valueDescription":"DHAX Regimen","ValueMeaning":{"publicId":"6734271","version":"1","preferredName":"DHAX Regimen","longName":"6734271","preferredDefinition":"A regimen consisting of dexamethasone, cytarabine and oxaliplatin that can be used to treat relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DHAX Regimen","conceptCode":"C159557","definition":"A regimen consisting of dexamethasone, cytarabine and oxaliplatin that can be used to treat relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87767AD4-6E46-73A9-E053-F662850A7104","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87767AD4-6E5F-73A9-E053-F662850A7104","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"877335D6-40CB-7B53-E053-F662850A3265","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"HARTLEYG","dateModified":"2019-05-01","changeDescription":"PTCL content","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6705584","version":"1","longName":"CCG PTCL (Center for Cancer Genomics - Peripheral T Cell Lymphoma)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6705585","version":"1","longName":"PTCL","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Pharmaceutical regimen","type":"Preferred Question Text","description":"Pharmaceutical regimen","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87736DDF-29CF-4755-E053-F662850AD45E","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-04-26","modifiedBy":"HARTLEYG","dateModified":"2019-05-01","changeDescription":"PTCL content","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}